Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $70.00

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price cut by Royal Bank of Canada from $80.00 to $70.00 in a research report report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. Other equities analysts have also issued research reports about the stock. Chardan Capital reiterated a […]

Related Keywords

Wisconsin ,United States ,Canada , ,Royal Bank ,Canaccord Genuity Group ,Merlin Capital ,Group Wealth Management ,Barclays ,Intellia Therapeutics Company Profile ,Financial Services Group Inc ,Penserra Capital Management ,Intellia Therapeutics Inc ,Intellia Therapeutics ,Free Report ,Genuity Group ,Moderate Buy ,Get Free Report ,Services Group ,Capital Management ,Wisconsin Investment Board ,Wealth Management ,Intellia Therapeutics Daily ,Nasdaq Ntla ,Intla ,Medical ,Lower Price Target ,Royal Bank Of Canada ,